Press Room

News / Aug 09, 2021

Our knowledge is available 365 days for you

Summer series

Knowledge 365 our experts content always available | Hovione

Our knowledge is available 365 days for you.

Count on our multidisciplinary teams to exchange knowledge, ideas, and experience to develop and improve your project. As a specialist integrated CDMO we are dedicated to helping you bring new and off-patent drugs to market faster.

Challenge us

 

Our scientists attend the leading events of the pharma industry throughout the year where they share their knowledge and present their innovative work.

 

Did you miss the articles on Pharmaceutical Technology, Drug Development & Delivery, On-Drug Delivery or Chemistry Today? You are still in time to read them. Access them here: 

 

pharmatech logo | Hovione

 

Drug Development and Delivery Logo | Hovione

 



Moving Beyond

Particle Size Control




Contributors:

João Henriques (Group Leader,

R&D Drug Product Development)

Mafalda Paiva (Group Leader, Analytical Development)


 


Improving Bioavailability

& Solubility: Each Molecule

Is Unique - Emerging Platforms

Address Extreme Compounds




Contributor: João Henriques

(Group Leader, R&D

Drug Product Development)


 
ondrugdelivery logo | Hovione

 

chemistry today chimica oggi logo | Hovione

 



Semi-Automation in

Inhaler Testing - Exploring

the Potential & Practicalities




Discussion with João Pereira

(Team Leader, R&D Analytical Development)

Raquel Borda d' Água

(Associate Analytical Chemist, R&D Analytical Development; Copley) 


 


Where Continuous Flow

can help in today’s

Pharmaceutical Industry




Panel Discussion with

Rudi Oliveira

(Scientist, R&D Process

Engineering and Scale-up)









































 

 

 

 

 

 

 

Did you miss our presentations at DDF, RDD, DDL or AIChE?

You are still in time to join. Access them here:

 

 

ddf summit 2021 logo | Hovione

 

rdd 2021 logo | Hovione

 



Technology & Innovation



Performance Enhancement Strategies for

Low Solubility APIs – do more with less




Authors: Mafalda Paiva &

João Henriques

 



Workshop Presentation



Fully Integrated

DPI Development

From API To Device




Authors: João Pereira,

Beatriz Noriega Fernandes

aiche 2020 logo | Hovione

 

ddl 2020 logo | Hovione

 



Predictive Scale-Up/Scale-Down for Production of Pharmaceuticals



Reaction Kinetic Model

Application to Speed up Development




Author: Filipe Ataíde

 



Presentation

and Paper



Spray-dried composite

formulation for lung

sustained release




Author: Beatriz Noriega Fernandes

















































































 

Also in the Press Room

See All

Aim to accelerate drug development and production with new technologies. By: Charlie Sternberg Hovione, an international integrated pharmaceutical development and manufacturing organization, and Microinnova Engineering, a leader in continuous process intensification, have partnered to advance the development of multi-purpose, plug-and-play modular equipment for flow chemistry. The companies will work together to test Microinnova’s modular manufacturing equipment, which is designed to offer greater flexibility, easier scalability, enhanced efficiency, and sustainable practices in active ingredient production, in an industrial setting. Together, the companies aim to accelerate process development, facilitate a seamless transition from lab to large-scale manufacturing, and ultimately reduce the time to market for pharmaceutical customers. “This collaboration with Microinnova underscores Hovione’s commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in our long-term drug substance strategy,” said Dr. Jean-Luc Herbeaux, CEO of Hovione. “This partnership will allow us to shape and validate emerging continuous manufacturing technologies, which can potentially accelerate drug development and production.” Dr. Dirk Kirschneck, Founder and Strategic Director at Microinnova, added, “This partnership reflects our shared vision to deliver modular manufacturing technologies that support pharmaceutical innovation and manufacturing excellence. We are proud to join forces with Hovione to showcase the capabilities of our next-generation modular equipment in a dynamic CDMO environment, demonstrating its versatility for multi-purpose manufacturing.”   Read the full article on ContractPharma.com  

Press Clipping

Hovione, Microinnova Partner to Test Modular Manufacturing Equipment

Sep 24, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025